Fennec Pharmaceuticals Inc (FENC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Fennec Pharmaceuticals Inc (FENC)

The EV/EBITDA price action for Fennec Pharmaceuticals (FENC) on the GURU.Markets platform is 0.00, driven by high sales profitability of the orphan drug and efficient digital management. Fennec Pharmaceuticals (FENC) relies on contract manufacturing via Pedmark without maintaining its own facilities, while the stability of its market position is ensured by a narrow focus on hearing protection for children undergoing cancer treatment.

FENC Fennec Pharma: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/10/2026

FENC (fennecpharma.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Fennec Pharmaceuticals Inc|FENC - Fair Value Consensus
- market capitalization indicators:
Market Value Fennec|FENC - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Fennec Pharmaceuticals|FENC - Accounting Capitalization|Market Capitalization to Book Value Ratio fennecpharma.com|FENC - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Fennec Pharmaceuticals|FENC - Long-Term Liabilities to Capital|Short-Term Debt to Equity Fennec Pharmaceuticals Inc.|FENC - Company Debts|Debt to Book Capitalization Ratio Fennec|FENC - Long-Term Debt|Company Short-Term Debts Fennec Pharmaceuticals|Quick Liquidity Indicator fennecpharma.com
- business earnings and investment ratios data:
FENC - Company Net Income|Future Profit Fennec Pharmaceuticals|FENC - Company Value to Net Income|Projected Price to Earnings Fennec Pharmaceuticals|FENC - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Fennec|FENC - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Fennec Pharmaceuticals|FENC - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months fennecpharma.com|FENC - Earnings per share increase in current year|Earnings growth forecast for next year Fennec Pharmaceuticals
Summary company analytics:FENC (Fennec Pharmaceuticals Inc)
Original product of Fennec Pharmaceuticals Inc.

This indicator compares the total enterprise value, including net debt, with its operational profitability before depreciation and taxes. By analyzing the EV/EBITDA chart, an investor assesses the extent to which market expectations align with actual cash flow. For Fennec Pharmaceuticals (FENC), this calculation is critical, as the monopoly status of the drug Pedmark must convert into sustainable profit growth. Low values confirm the asset is undervalued given its patent-protected market positions.

Competitor analysis

Incyte Corp. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HCM|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA dayonebio.com|Monopar Therapeutics Inc. (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (I-Mab Biopharma Co., Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Heron Therapeutics Inc (HRTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nuvectis Pharma, Inc. (NVCT)|CHRS - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Corbus Pharmaceuticals Holdings CRBP|Cardiff Oncology Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BYSI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BioAtla, Inc.|LIXT: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Citius Pharmaceuticals, Inc. CTXR|Enterprise Value to EBITDA Ratio CLRB|Company Value to EBITDA BioLineRx Ltd BLRX|Enterprise Value to EBITDA Ratio CANF (Can-Fite BioPharma, Ltd.)|APRE (aprea.com) - Business Value to Operating Income Before Depreciation|Kazia Therapeutics Limited - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SLXN (Silexion Therapeutics Corp.)|NuCana Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix Inc.)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Therapeutics (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio, Inc.|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Inc (PRTG)